Stanford Neuroscientist Andrew Huberman on AI Companies Becoming Biotech Firms and the Next Era of Brain-Machine Interfaces
Episode 494 of Invest Like the Best features Stanford University neuroscientist Andrew Huberman, discussing the shift in neuroscience from 'reading' to 'writing' to the brain, and why he believes leading AI companies are evolving toward biotechnology.
ImportanceMaterialEvidenceE2 unreplicatedWrite-upQuick
On October 6, 2026, Invest Like the Best released Episode 494, titled "Reading and Writing the Brain," featuring Andrew Huberman, a neuroscientist and professor at Stanford University. The episode focuses on the next phase of neuroscience, moving from decades of reading brain activity to precisely writing to specific brain states.
According to the publisher's show notes, Huberman explains why he thinks leading AI companies are building toward this capability and identifies understanding waking brain states as the problem he most wants to see solved. The discussion also covers topics such as AI labs becoming biotech companies, using viral injections of algae genes to boost motivation, and eye tricks for falling asleep faster.
For investors and researchers interested in the intersection of AI and biotechnology, this episode offers a unique perspective on how top AI firms may be positioning themselves in neuro-modulation technologies. While a full transcript is not currently available, the guest's academic credentials and the specific topics listed make this resource valuable for understanding the potential application of AI in life sciences.